Orthobiologics Market
Orthobiologics Market Forecasts to 2032 - Global Analysis By Product Type (Bone Grafts, Growth Factors, Platelet-Rich Plasma (PRP), Stem Cells, Cell-Based Therapies and Other Product Types), Distribution Channel, Application, End User and By Geography
|
Years Covered |
2024-2032 |
|
Estimated Year Value (2025) |
US $7.2 BN |
|
Projected Year Value (2032) |
US $11.2 BN |
|
CAGR (2025-2032) |
6.5% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Orthobiologics Market is accounted for $7.2 billion in 2025 and is expected to reach $11.2 billion by 2032 growing at a CAGR of 6.5% during the forecast period. Orthobiologics is the use of biological materials and substances to promote healing and repair in musculoskeletal conditions. These therapies include stem cells, platelet-rich plasma (PRP), growth factors, and extracellular matrix proteins, which are derived from the body or synthesized. Orthobiologics are often used in orthopedics to treat injuries or degenerative diseases by stimulating tissue regeneration, reducing inflammation, and accelerating healing processes. This approach offers a more natural alternative to surgery, with the potential for improved outcomes and reduced recovery times for patients with joint, ligament, tendon, or bone injuries.
According to the ISAPS Global Survey, the number of procedures performed by plastic surgeons increased by 11.2% in 2022. About 18.8 million non-surgical and 14.9 million surgical procedures were performed worldwide, continuing the trend of a 41.3% increase over the last four years.
Market Dynamics:
Driver:
Growing demand for minimally invasive procedures
The growing demand for minimally invasive procedures in the market is driven by their ability to offer faster recovery times, reduced risk of complications, and less post-operative pain compared to traditional surgeries. Patients increasingly prefer these procedures due to their effectiveness in treating musculoskeletal injuries with minimal disruption to surrounding tissues. As technologies improve and awareness rises, the adoption of minimally invasive Orthobiologic treatments like PRP and stem cell therapies is expected to continue growing, transforming the landscape of orthopedic care.
Restraint:
Lack of standardization
The lack of standardization in the market poses significant challenges, including inconsistent treatment outcomes and safety concerns. Without clear guidelines, the quality and efficacy of therapies like stem cell injections and platelet-rich plasma (PRP) can vary widely, leading to unpredictable results for patients. This inconsistency undermines patient trust and can hinder widespread adoption. Additionally, the absence of standardized protocols complicates regulatory oversight, increasing the risk of unproven or unsafe treatments entering the market and potentially harming patients.
Opportunity:
Rising awareness of regenerative medicine
Rising awareness of regenerative medicine is significantly influencing the market, as patients and healthcare providers recognize its potential for healing and tissue repair. Regenerative treatments, such as stem cell therapy and platelet-rich plasma (PRP), offer promising alternatives to traditional surgeries, addressing musculoskeletal injuries and degenerative conditions. As education and research advance, more people are seeking out these innovative treatments for faster recovery and improved outcomes. This growing awareness is driving the increasing demand and expansion of regenerative medicine in orthobiologic applications.
Threat:
High cost of treatments
The high cost of treatments in the market limits access to these advanced therapies for many patients, particularly those without adequate insurance coverage. Expensive procedures like stem cell therapy or platelet-rich plasma (PRP) injections can be financially burdensome, leading some individuals to forgo potentially beneficial treatments. This not only creates inequities in healthcare access but also slows the widespread adoption of Orthobiologics, as patients may opt for more affordable, conventional treatments, even if they may not offer the same regenerative benefits.
Covid-19 Impact:
The COVID-19 pandemic significantly impacted the market by disrupting supply chains, delaying elective procedures, and limiting patient access to treatments. Many orthopedic clinics and hospitals paused non-emergency services, leading to a reduction in the demand for regenerative therapies like stem cell treatments and PRP injections. Additionally, financial constraints and concerns over infection risks led patients to delay or forgo treatments. However, the pandemic also accelerated interest in minimally invasive and non-surgical options, which may drive future growth in the market.
The lumbar fusion segment is expected to be the largest during the forecast period
The lumbar fusion segment is expected to account for the largest market share during the forecast period such as bone grafts or stem cells, to promote the healing and fusion of vertebrae in the lower back. By integrating orthobiologic therapies, lumbar fusion aims to enhance healing, reduce complications, and improve patient outcomes. As minimally invasive techniques gain traction, the demand for regenerative treatments in spinal surgery is expected to increase, offering better recovery options for patients.
The dental clinics segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the dental clinics segment is predicted to witness the highest growth rate. These biologic therapies help accelerate tissue regeneration, reduce inflammation, and improve the overall success of dental surgeries. As awareness of regenerative medicine grows, more dental professionals are integrating Orthobiologics into their practice, providing patients with advanced, minimally invasive options for faster recovery and better long-term results, boosting the demand within the dental sector.
Region with largest share:
During the forecast period, the Asia Pacific region is expected to hold the largest market share due to increasing healthcare awareness. Countries like Japan, China, and India are seeing greater adoption of treatments such as stem cell therapy, platelet-rich plasma (PRP), and bone grafts. Growing healthcare infrastructure, along with a shift towards minimally invasive procedures, is driving demand for Orthobiologics. The market is also supported by improving regulatory frameworks and increasing investments in medical research and technology.
Region with highest CAGR:
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR. Technological advancements in regenerative medicine, including stem cell therapies, gene therapies, and platelet-rich plasma (PRP) treatments, have boosted the efficacy of orthobiologic treatments. These innovations have led to greater adoption among both patients and healthcare providers.Moreover, As more patients and healthcare professionals learn about the benefits of orthobiologic therapies, such as accelerated healing and reduced dependency on traditional drugs or surgeries, demand for these treatments has risen.
Key players in the market
Some of the key players in Orthobiologics Market include Bioventus LLC, Nuvasive, Inc., Anika Therapeutics, Inc., Alphatec Spine, Inc., Medtronic plc, Stryker Corporation, Globus Medical, Inc., Xtant Medical Holdings, Inc., Sanofi S.A., Orthofix Medical Inc., Bone Therapeutics SA, RTI Surgical, Inc. , Kuros Biosciences Ltd. , Smith & Nephew plc, Integra LifeSciences Holdings Corporation , Seaspine Holdings Corporation and Arthrex, Inc.
Key Developments:
In March 2025, Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies. DR-0201 is a potential first-in-class CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted phagocytosis..
In March 2024, Stryker announced a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC, a family-owned investment firm specializing in the neuro-musculoskeletal space, to create a newly formed company called VB Spine, LLC.
Product Types Covered:
• Bone Grafts
• Growth Factors
• Platelet-Rich Plasma (PRP)
• Stem Cells
• Cell-Based Therapies
• Other Product Types
Distribution Channels Covered:
• Direct Sales
• Indirect Sales
• E-Commerce Platforms
Applications Covered:
• Cervical Fusion
• Lumbar Fusion
• Thoracic Fusion
• Hip Replacement
• Shoulder Reconstruction
• Dental Implants
• Wound Healing
• Microfracture Surgery
• Ligament Repair
• Other Applications
End Users Covered:
• Hospitals
• Ambulatory Surgical Centers
• Orthopedic Clinics
• Dental Clinics
• Rehabilitation Centers
• Research Institutes
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Orthobiologics Market, By Product Type
5.1 Introduction
5.2 Bone Grafts
5.2.1 Autografts
5.2.2 Allografts
5.2.3 Synthetic Bone Grafts
5.3 Growth Factors
5.3.1 Bone Morphogenetic Proteins (BMPs)
5.3.2 Platelet-Derived Growth Factor (PDGF)
5.3.3 Vascular Endothelial Growth Factor (VEGF)
5.3.4 Transforming Growth Factor-beta (TGF-?)
5.3.5 Insulin-like Growth Factor (IGF)
5.4 Platelet-Rich Plasma (PRP)
5.5 Stem Cells
5.5.1 Mesenchymal Stem Cells (MSCs)
5.5.2 Hematopoietic Stem Cells
5.5.3 Induced Pluripotent Stem Cells (iPSCs)
5.6 Cell-Based Therapies
5.6.1 Autologous Cell Therapy
5.6.2 Allogeneic Cell Therapy
5.7 Other Product Types
6 Global Orthobiologics Market, By Distribution Channel
6.1 Introduction
6.2 Direct Sales
6.3 Indirect Sales
6.4 E-Commerce Platforms
7 Global Orthobiologics Market, By Application
7.1 Introduction
7.2 Cervical Fusion
7.3 Lumbar Fusion
7.4 Thoracic Fusion
7.5 Hip Replacement
7.6 Shoulder Reconstruction
7.7 Dental Implants
7.8 Wound Healing
7.9 Microfracture Surgery
7.10 Ligament Repair
7.11 Other Applications
8 Global Orthobiologics Market, By End User
8.1 Introduction
8.2 Hospitals
8.3 Ambulatory Surgical Centers
8.4 Orthopedic Clinics
8.5 Dental Clinics
8.6 Rehabilitation Centers
8.7 Research Institutes
8.8 Other End Users
9 Global Orthobiologics Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Bioventus LLC
11.2 Nuvasive, Inc.
11.3 Anika Therapeutics, Inc.
11.4 Alphatec Spine, Inc.
11.5 Medtronic plc
11.6 Stryker Corporation
11.7 Globus Medical, Inc.
11.8 Xtant Medical Holdings, Inc.
11.9 Sanofi S.A.
11.10 Orthofix Medical Inc.
11.11 Bone Therapeutics SA
11.11 RTI Surgical, Inc.
11.13 Kuros Biosciences Ltd.
11.14 Smith & Nephew plc
11.15 Integra LifeSciences Holdings Corporation
11.16 Seaspine Holdings Corporation
11.17 Arthrex, Inc.
List of Tables
1 Global Orthobiologics Market Outlook, By Region (2024-2032) ($MN)
2 Global Orthobiologics Market Outlook, By Product Type (2024-2032) ($MN)
3 Global Orthobiologics Market Outlook, By Bone Grafts (2024-2032) ($MN)
4 Global Orthobiologics Market Outlook, By Autografts (2024-2032) ($MN)
5 Global Orthobiologics Market Outlook, By Allografts (2024-2032) ($MN)
6 Global Orthobiologics Market Outlook, By Synthetic Bone Grafts (2024-2032) ($MN)
7 Global Orthobiologics Market Outlook, By Growth Factors (2024-2032) ($MN)
8 Global Orthobiologics Market Outlook, By Bone Morphogenetic Proteins (BMPs) (2024-2032) ($MN)
9 Global Orthobiologics Market Outlook, By Platelet-Derived Growth Factor (PDGF) (2024-2032) ($MN)
10 Global Orthobiologics Market Outlook, By Vascular Endothelial Growth Factor (VEGF) (2024-2032) ($MN)
11 Global Orthobiologics Market Outlook, By Transforming Growth Factor-beta (TGF-?) (2024-2032) ($MN)
12 Global Orthobiologics Market Outlook, By Insulin-like Growth Factor (IGF) (2024-2032) ($MN)
13 Global Orthobiologics Market Outlook, By Platelet-Rich Plasma (PRP) (2024-2032) ($MN)
14 Global Orthobiologics Market Outlook, By Stem Cells (2024-2032) ($MN)
15 Global Orthobiologics Market Outlook, By Mesenchymal Stem Cells (MSCs) (2024-2032) ($MN)
16 Global Orthobiologics Market Outlook, By Hematopoietic Stem Cells (2024-2032) ($MN)
17 Global Orthobiologics Market Outlook, By Induced Pluripotent Stem Cells (iPSCs)
(2024-2032) ($MN)
18 Global Orthobiologics Market Outlook, By Cell-Based Therapies (2024-2032) ($MN)
19 Global Orthobiologics Market Outlook, By Autologous Cell Therapy (2024-2032) ($MN)
20 Global Orthobiologics Market Outlook, By Allogeneic Cell Therapy (2024-2032) ($MN)
21 Global Orthobiologics Market Outlook, By Other Product Types (2024-2032) ($MN)
22 Global Orthobiologics Market Outlook, By Distribution Channel (2024-2032) ($MN)
23 Global Orthobiologics Market Outlook, By Direct Sales (2024-2032) ($MN)
24 Global Orthobiologics Market Outlook, By Indirect Sales (2024-2032) ($MN)
25 Global Orthobiologics Market Outlook, By E-Commerce Platforms (2024-2032) ($MN)
26 Global Orthobiologics Market Outlook, By Application (2024-2032) ($MN)
27 Global Orthobiologics Market Outlook, By Cervical Fusion (2024-2032) ($MN)
28 Global Orthobiologics Market Outlook, By Lumbar Fusion (2024-2032) ($MN)
29 Global Orthobiologics Market Outlook, By Thoracic Fusion (2024-2032) ($MN)
30 Global Orthobiologics Market Outlook, By Hip Replacement (2024-2032) ($MN)
31 Global Orthobiologics Market Outlook, By Shoulder Reconstruction (2024-2032) ($MN)
32 Global Orthobiologics Market Outlook, By Dental Implants (2024-2032) ($MN)
33 Global Orthobiologics Market Outlook, By Wound Healing (2024-2032) ($MN)
34 Global Orthobiologics Market Outlook, By Microfracture Surgery (2024-2032) ($MN)
35 Global Orthobiologics Market Outlook, By Ligament Repair (2024-2032) ($MN)
36 Global Orthobiologics Market Outlook, By Other Applications (2024-2032) ($MN)
37 Global Orthobiologics Market Outlook, By End User (2024-2032) ($MN)
38 Global Orthobiologics Market Outlook, By Hospitals (2024-2032) ($MN)
39 Global Orthobiologics Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
40 Global Orthobiologics Market Outlook, By Orthopedic Clinics (2024-2032) ($MN)
41 Global Orthobiologics Market Outlook, By Dental Clinics (2024-2032) ($MN)
42 Global Orthobiologics Market Outlook, By Rehabilitation Centers (2024-2032) ($MN)
43 Global Orthobiologics Market Outlook, By Research Institutes (2024-2032) ($MN)
44 Global Orthobiologics Market Outlook, By Other End Users (2024-2032) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
